<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=LDLRAD4</id>
	<title>LDLRAD4 - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=LDLRAD4"/>
	<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=LDLRAD4&amp;action=history"/>
	<updated>2026-06-13T05:50:21Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.43.6</generator>
	<entry>
		<id>https://transhumanist.ru/index.php?title=LDLRAD4&amp;diff=3953&amp;oldid=prev</id>
		<title>OdysseusBot: Новая страница: «Low-density lipoprotein receptor class A domain-containing protein 4 [C18orf1]  ==Publications==  {{medline-entry |title=Epigenetics of neuroinflammation: Immune...»</title>
		<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=LDLRAD4&amp;diff=3953&amp;oldid=prev"/>
		<updated>2021-04-29T18:53:23Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «Low-density lipoprotein receptor class A domain-containing protein 4 [C18orf1]  ==Publications==  {{medline-entry |title=Epigenetics of neuroinflammation: Immune...»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Low-density lipoprotein receptor class A domain-containing protein 4 [C18orf1]&lt;br /&gt;
&lt;br /&gt;
==Publications==&lt;br /&gt;
&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Epigenetics of neuroinflammation: Immune response, inflammatory response and cholinergic synaptic involvement evidenced by genome-wide DNA methylation analysis of delirious inpatients.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32590150&lt;br /&gt;
|abstract=Previously our study has shown that the DNA methylation (DNAm) levels at CpG sites in the pro-inflammatory cytokine gene, [[TNF]]-alpha, decrease along with aging, suggesting the potential role of DNAm in aging and heightened inflammatory process leading to increased risk for delirium. However, DNAm differences between delirium cases and non-delirium controls have not been investigated directly. Therefore, we examined genome-wide DNAm differences in blood between patients with delirium and controls to identify useful epigenetic biomarkers for delirium. Data from a total of 87 subjects (43 delirium cases) were analyzed by a genome-wide DNAm case-control association study. A genome-wide significant CpG site near the gene of [[LDLRAD4]] was identified (p = 5.07E-8). In addition, over-representation analysis showed several significant pathways with a false discovery rate adjusted p-value &amp;lt; 0.05. The top pathway with a Gene Ontology term was immune response, and the second top pathway with a Kyoto Encyclopedia of Genes and Genomes term was cholinergic synapse. Significant DNAm differences related to immune/inflammatory response were shown both at gene and pathway levels between patients with delirium and non-delirium controls. This finding indicates that DNAm status in blood has the potential to be used as epigenetic biomarkers for delirium.&lt;br /&gt;
&lt;br /&gt;
|keywords=* Aging&lt;br /&gt;
* Delirium&lt;br /&gt;
* Genome-wide DNA methylation&lt;br /&gt;
* Immune response&lt;br /&gt;
* Inflammatory response&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486988&lt;br /&gt;
}}&lt;/div&gt;</summary>
		<author><name>OdysseusBot</name></author>
	</entry>
</feed>